Appln. No.: 10/572,671 Group Art Unit No.: 1624

## Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application.

## **Listing of Claims:**

Claims 1-8 (Cancelled).

9. (New): A compound of formula (I):

$$(R^2)_m$$
 $(CH_2)_p$ 
 $(R^3)_n$ 
 $(I)$ 

wherein:

R<sup>1</sup> represents hydrogen or methyl;

R<sup>2</sup> represents hydrogen or methyl;

m represents 1;

R<sup>3</sup> represents hydrogen, methyl or halogen;

R<sup>4</sup> and R<sup>5</sup> independently represent hydrogen or methyl;

n represents 1;

p represents 1 or 2;

J represents CH<sub>2</sub>, CO, or O;

A represents phenyl optionally substituted by a halogen atom;

or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

10. (New): A compound which is:

3-[(3-Chlorophenyl)methyl]-8-(1-piperazinyl)quinoline;

Appln. No.: 10/572,671 Group Art Unit No.: 1624

(3-Chlorophenyl)[8-(1-piperazinyl)-3-quinolinyl]methanone;

3-(Phenyloxy)-8-(1-piperazinyl)quinoline;

or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

- 11. (New): A pharmaceutical composition which comprises the compound, salt, or hydrate according to claim 9 and a pharmaceutically acceptable carrier or excipient.
- 12. (New): A pharmaceutical composition which comprises the compound, salt, or hydrate according to claim 10 and a pharmaceutically acceptable carrier or excipient.
- 13. (New): A method of treating a cognitive memory disorder which comprises administering a therapeutically effective amount of the compound, salt, or hydrate according to claim 9 to a patient in need thereof, wherein the cognitive memory disorder is selected from age related cognitive decline, mild cognitive impairment, and cognitive deficits in schizophrenia.
- 14. (New): A method of treating a cognitive memory disorder which comprises administering a therapeutically effective amount of the compound, salt, or hydrate according to claim 10 to a patient in need thereof, wherein the cognitive memory disorder is selected from age related cognitive decline, mild cognitive impairment, and cognitive deficits in schizophrenia.
- 15. (New): A method of treating depression or anxiety which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.
- 16. (New): A method of treating depression or anxiety which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 10.
- 17. (New): A method of treating obesity which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.

Appln. No.: 10/572,671 Group Art Unit No.: 1624

18. (New): A method of treating obesity which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 10.

- 19. (New): A method of Alzheimers disease which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 9.
- 20. (New): A method of treating Alzheimers disease which comprises administering to a patient in need thereof a therapeutically effective amount of the compound, salt, or hydrate according to claim 10.